ONCAlert | 2017 San Antonio Breast Cancer Symposium

Tarextumab in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Eileen M. O’Reilly, MD
Published Online:1:15 PM, Mon January 23, 2017

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, and professor of medicine, Weill Cornell Medicine, discusses results of a randomized phase II trial of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.